natgillin/translations-raw huggingface dataset:
wherein the compound is of Formula (II-a): or a pharmaceutically acceptable salt thereof; or wherein the compound is of Formula (II-b): or a pharmaceutically acceptable salt thereof. 
pri čemu je spoj s Formulom (II-a): ili njegova farmaceutski prihvatljiva sol; ili pri čemu je spoj s Formulom (II-b): ili njegova farmaceutski prihvatljiva sol.
The marking device according to claim 1, wherein the mowing drum and rolling elements are driven reversibly by a motor. 
Uređaj sukladno zahtjevu 6, gdje su bubanj za košenje 1 rotirajući elementi vođeni na reverzibilan način od strane motora.
An embodiment of the present invention is a compound of selective peroxisome proliferator activated receptor modulator (SPPARM) or a compound having the PPARY partial agonist activity, which has a structural formula I, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein: R1 and R2 are each independently: methyl or ethyl. 
Izvedba ovog izuma je spoj koji je selektivni modulator receptora aktiviranog peroksisomskim proliferatorom (SPPARM) ili spoj s aktivnošću parcijalnog agonista PPARy, strukturne formule I, iH H =
a tautomer thereof or a pharmaceutically acceptable salt of the compound or tautomer, wherein: 
zh pi njegov tautomer ili farmaceutski prihvatljiva sol spoja ili tautomer, pri čemu:
deprotecting the compound of Formula XXIII to give a compound of Formula XXIV; 
Formula XXHI c. skidanje zaštite sa spoja Formule XXIII, čime se dobiva spoj Formule XXIV: a.
decreasing the total amount of soluble amyloid-B in the retinal ganglion cell layer of a subject suffering from glaucoma, optic neuritis, or lattice dystrophy; or retaining or decreasing ocular pressure in the eyes of a subject suffering from glaucoma, optic neuritis, or lattice dystrophy; wherein the antibody or functional fragment thereof comprises: 
Protutijelo, ili njegov funkcionalni dio, u skladu s patentnim zahtjevom 4, naznačeno time što je namijenjeno upotrebi u liječenju u skladu s patentnim zahtjevom 4 namijenjenom smanjivanju ukupne količine topljivog amiloida-B u sloju ganglijskih stanica u mrežnici kod subjekta koji boluje od glaukoma, optičkog neuritisa ili retikularne distrofije.
Also said foils, pieces, boards of materials being different from wood, are then incorporated into the composite of pieces of wood by gluing, whereby the arrangement and the sequence of the pieces of wood and the pieces of materials being different from wood can be arbitrarily varied. 
Također navedene folije, komadi, ploče ili materijali koji su različiti od drva, se tada ugrađuju u kompoziciju od komada od drva pomoću lijepljenja, pri čemu raspored i slijed komada od drva i komada od materijala koji je različit od drva može biti proizvoljno mijenjan.
The method according to claim 1, wherein the bicontinuous micro-emulsion contains at least 15 mM metal nanoparticles calculated on the aqueous phase. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što dvokontinualna mikroemulzija sadrži najmanje 15 mM metalnih nanočestica, obračunato na vodenu fazu.
Container (1) according to claim 1, wherein the second component (4) is made by mineral oils or a mixture of mineral oils, hydrocarbons or a mixture of hydrocarbons, or by Isoparaffin C9-C12. 
Spremnik (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što drugu komponentu (4) čine mineralna ulja ili smjesa mineralnih ulja, ugljikovodici ili smjesa ugljikovodika, ili izoparafin C9-C12.
An isolated antibody comprising a human IgG1 Fc domain, wherein the human IgG1 Fc domain comprises a glycosylated asparagine residue at amino acid position 298, according to EU numbering; and a serine or threonine residue at amino acid position 300, according to EU numbering. 
Izolirano protutijelo koje sadrži ljudsku IgG1 Fc domenu, naznačeno time da ljudska IgG1 Fc domena sadrži glikozilirani asparaginski ostatak na položaju aminokiseline 298, u skladu s EU označavanjem; 1 sermski ili treoninski ostatak na položaju aminokiseline 300, u skladu s EU označavanjem.
the conveyor belt or the shaking conveyor (2) is started in such a way as to supply a flow rate of solid comprised between 250 kg/h and 500 kg/h, solid which is introduced into the annular zone (4) using the funnel (3), 
- transportna traka ili vibrirajući transporter (2) se pokreće na takav način da osigura brzinu protoka krutih čestica od između 250 kg/h i 500 kg/h, koja se krutina uvodi u prstenastu zonu (4) pomoću lijevka (3),
The pharmaceutical composition of claim 6 or the peptide or polynucleotide of claim 15, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, endometriosis, esophageal cancer, gastric cancer, diffused type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 6, ili peptid ili polinukleotid u skladu s patentnim zahtjevom 15, naznačen time što se rak bira iz skupine koju čine rak mokraćnog mjehura, rak dojke, rak vrata maternice, kolangiocelularni karcinom, CML, kolorektalni rak, endometrioza, rak jednjaka, rak želuca, rak želuca difuznog tipa, rak jetre, NSCLC, limfom, osteosarkom, rak jajnika, gušterače rak, rak prostate, bubrežni karcinom, SCLC, tumor mekog tkiva i tumor na testisima.
The polyalkylene oxide-adenosine deaminase conjugate of claim 7, wherein the recombinant adenosine deaminase comprises one or more polyethylene glycol strands attached to epsilon amino groups of one or more Lys residues of the recombinant adenosine deaminase. 
Konjugat adenozin deaminaze i polialkilen oksida u skladu s patentnim zahtjevom 7, naznačen time, da rekombinantna adenozin deaminaza sadržava jednu ili više polietilen glikol niti vezanih na epsilon amino skupine jednog ili više Lys ostataka rekombinantne adenozin deaminaze.
The device of claim 13, wherein the first distance zone and the second distance zone are circle rings around the respective candidate point. 
Naprava (1200) u skladu s patentnim zahtjevom 13 ili 14, naznačena time što su zona prve udaljenosti (401a) i zona druge udaljenosti (401c) kružni prsteni oko određene moguće točke (411).
that the width of the thermal sealing means is adapted for performing a thermal sealing extending across a part of the width of the film webs, so that at least one and preferably two or more unbroken longitudinal areas where no thermal sealing occurs appear in the longitudinal direction of the film webs. 
što se poprečno zavarivanje toplinom vrši duž jednog dijela širine trake filma tako da najmanje jedna, a prvenstveno dvije ili više neprekidnih uzdužnih područja (9) nastaje tamo gdje se ne vrši zavarivanje toplinom, u uzdužnom smjeru trake filma (3), i
The CD 154 binding protein according to claim 1 or claim 2, wherein the binding protein further comprises a variant Fc region that confers reduced effector function compared to a native or parental Fc region, and wherein said variant Fc region is preferably a hybrid Fc region comprising sequences from more than one Ig Fc domain type. 
Protutijelo protiv CD154, ili njegov CD154-vežući fragment, u skladu s patentnim zahtjevom 1, naznačen time što protutijelo, ili njegov fragment, dodatno sadrži varijanta Fc područja koje je hibridno Fc područje koje sadrži sljedove iz više od jedne domene Ig Fc tipa.
at least one water swelling anionic polymer and optionally excipients, the resulting tablet providing a pH-dependent release characteristic with a faster release characteristic in the range of pH<4.5, and a slower and further on pH-independent release characteristic in the range from pH 4.5 to 7.5. 
Formulacija tablete produljenog oslobađanja u skladu sa zahtjevom 1, naznačena time, da rezultirajuća tableta osigurava pH-ovisno oslobađanje karakterizirano bržim oslobađanjem karakterističnim u rasponu pH < 4.5, te sporijim i nadalje pH-neovisnim oslobađanjem karakterističnim u rasponu od pH 4.5 do 7.5.
Transfer apparatus according to any of the clauses 1-10, wherein each connection of the coupler to neighbouring carriers comprises a coupler axis about which the coupler is pivotable relative to the carrier comprising said connection. 
Prijenosni uređaj prema bilo kojem zahtjevu 1-10., naznačen time da svaki spoj spojnice (9) sa susjednim nosačima (8) sadrži os spojnice oko koje se okreće spojnica (9) u odnosu na nosač (8) koji sadrži rečeni spoj.
A combination according to claim 8 wherein the active compound (c) is selected from the group consisting of (a) PDE IV inhibitors and (b) cortiocosteroids. 
Kombinacija u skladu s patentnim zahtjevom 8, naznačena time, da je djelatni spoj (c) odabran iz skupine koju čine (a) B2-agonisti i (b) kortikosteroidi.
A device as claimed in any one of the preceding claims wherein the or each pocket (7A-7C) is a channel running substantially vertically along its respective baffle (5) so that, in use, water drains from the baffles on to a surface on which the wheel is travelling. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje je svaki džep (7A-7C) kanal, koji prolazi uglavnom okomito uz odgovarajuću žlijebnu pregradu (5), tako da se, prilikom upotrebe, voda cijedi sa žlijebnih pregrada na površinu po kojoj se kreće vozilo.
Preferably the methylotrophic yeast cell is selected from the group consisting of Candida, Hansenula, Pichia and Toruplosis, especially a Pichia pastoris cell. 
Garnitura prema zahtjevu 9, naznačena time, da spomenuta stanica je stanica kvasca, najbolje metilotrofička stanica kvasca, prednosno odabrana iz skupine koja se sastoji od stanica Candida, Hansenula, Pichia i Toruplosis, posebno stanica Pichia pastoris.
step c) is carried out in the presence of a solvent which is acetic acid or a mixture of acetic acid with an alcohol or with an ester. 
faza skidanja zaštite P1 provodi se u prisutnosti otapala koje je octena kiselina ili smjesa octene kiseline i alkohola ili estera.
about 1 to about 3 pH units below the pI of the polypeptide; or 
Postupak prema patentnom zahtjevu 4, naznačen time, da je pH otprilike 1 do otprilike 3 pH jedinice ispod pI protutijela.
The methanol was distilled out completely and to the residue, 100 ml of isopropyl alcohol was added and stirred for further 30 min at 60-65° C. Cooled to 28-32° C. Stirred the material at 28-32° C. for 3 hrs, filtered & washed with 20.0 ml of isopropyl alcohol and dried at 60-65° C. for 8 hrs to obtain 10.6 g of nebivolol hydrochloride (I). 
Metanol je potpuno uklonjen destilacijom a talogu je dodano 100 ml izopropil alkohola te je miješano tijekom daljnjih 30 minuta na 60-65 *C. Ohladeno na 28-32 *C. Materijal je miješan na 28-32 "C tijekom 3 sata, profiltriran & ispran s 20,0 ml izopropil alkohola i osušen na 60-65 "C tijekom 8 sati da bi se dobilo 10,6 g nebivolol hidroklorida (I).
a conduit having a proximal end and a distal end, wherein the proximal end allows fluid communication from a deagglomerator outlet port to the distal end of the conduit, wherein the airflow adaptor further comprises at least one second conduit for allowing air to flow from a proximal end of the adaptor to a distal end of the adaptor independently of the airflow in the conduit when a breath induced low pressure is applied to the distal end of the airflow adaptor, 
703) koja ima proksimalni kraj i distalni kraj, adaptor protoka zraka (100; 200; 300; 501; 601; 702) dalje obuhvaća barem jednu drugu cijev (102-105; 204-206; 304-306; 502-505; 603-606) za omogućavanje strujanja zraka od proksimalnog kraja adaptora (100; 200; 300; 501; 601; 702) do distalnog kraja adaptora (100; 200;
The pharmaceutical composition for use according to claim 4, further comprising a cytokine selected from the group consisting of IL-2, IL-3, IL-6, IL-11, IL-12, IL7, IL15, IL21, granulocyte macrophage colony stimulating factor, alpha, beta or gamma interferon and erythropoietin. 
Farmaceutski pripravak namijenjen upotrebi u liječenju neoplazije prema zahtjevu 20, te navedeni pripravak nadalje sadrži citokin odabran 1z skupine koju čine IL-2, IL -3, IL -6, IL -11, IL-12, IL-7, IL -15, IL-21, faktor stimulacije kolonija granulocita i makrofaga, alfa, beta ili gama interferon i eritropoetin.
Further evaluation of PS188 (SEQ ID NO:5) by transfection of human control muscle cells or peripheral blood mononuclear cells (PB-MNCs). 
"Nekodirajući oligonukleotid sastoji se od slijeda 5' ucagcuucuguuagccacug 3' (SEQ ID NO;5).
A pharmaceutical composition comprising, together with a pharmaceutically acceptable carrier or diluent, the compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt or ester thereof; and an anticancer agent selected from the group consisting of anticancer alkylating agents, anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum-coordinatedcomplex compounds, anticancer camptothecin derivatives, anticancer tyrosine kinase inhibitors, monoclonal antibodies, biological response modifiers, and other anticancer agents, wherein the definition of each anticancer agent is the same as defined in Claim 20, or a pharmaceutically acceptable salt thereof. 
Farmaceutski pripravak koji sadrži, zajedno s farmaceutski prikladnim nosačem ili punilom, spoj prema bilo kojem od zahtjeva 1 do 15, ili njegovu farmaceutski prikladnu sol ili ester; i citostatik odabran iz grupe koju čine alkilirajući citostatici, antimetaboliti citostatici, citostatici antibiotici, biljni citostatici, platinom-koordinirani kompleksni spojevi citostatici, citostatici derivati kamptotecina, citostatici inhibitori tirozin kinaze, monoklonska protutijela, modulatori biološkog odgovora, i drugi citostatici, gdje je definicija svake vrste citostatika kako je dano u zahtjevu 20, ili njihovu farmaceutski prikladnu sol ili ester.
reacting compound (12), or tautomer, or salt thereof, with an activated biphenylic compound to obtain a compound according to formula (13), or tautomer, or salt thereof, 
b) reakcija spoja prema formuli (12) ili njegove soli, s aktiviranim (naime metaliranim) bifenilnim spojem, kako bi se dobio spoj u skladu sa sljedećom formulom (13) ili njegova sol: gdje RI je vodikova ili dušikova zaštitna skupina, i
wherein the 3′ PPT is absent or otherwise non-functional, wherein the retroviral RNA vector transfer cassette is integration defective, and wherein the integration-defective retroviral RNA vector transfer cassette can be reverse-transcribed, wherein the packaging cell line provides proteins for the retroviral RNA vector transfer cassette to be packaged. 
Postupak za proizvodnju čestica vektora manjkavog u integraciji, koji obuhvaća transfekciju stanične linije za pakiranje retrovirusnom vektorskom kazetom za prijenos manjkavom u integraciji kojoj nedostaje 3’-PPT, gdje stanična linija za pakiranje osigurava proteine za pakiranje retrovirusnog vektora.
The method of claim 1, wherein if the size of the transform unit is 8x8, the significant flags, the coefficient signs and the coefficient levels are inversely scanned in a unit of a subset to generate a plurality of subsets and the quantized block is generated by inversely scanning the plurality of subsets according to the inverse scan pattern which is determined by the intra prediction mode. 
Postupak prema Zahtjevu 1, gdje ukoliko je veličina transformacijske jedinice 8x8, značajne oznake, znakovi koeficijenata i razine koeficijenata se inverzno skeniraju u jedinici podskupa kako bi generirali podskupove i generira se kvantizirani blok inverznim skeniranjem podskupova prema obrascu inverznog skeniranja koji se određuje pomoći intrapredikcijskog režima.
optionally converting the thus obtained (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol into an acid addition salt. 
(d) opcionalno pretvaranje tako dobivenog (1R,2R)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenola u kiselo adicijsku sol.
Example 4: Consistency of the clot 
Broj objave europskog patenta:
The glycosylated human SAP polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO: 1. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da polipeptid sadržava sekvencu aminokiselina koja je barem 85%, barem 90%, barem 95% ili barem 99% identična sekvenci aminokiselina od SEQ ID NO: 1 ili sadržava aminokiselinsku sekvencu SEQ ID NO: 1.
The system of claim 1 wherein the formation systems are pulsed power formation systems. The system of claim 1 wherein the formation systems comprise a plurality of power and control units coupled to individual ones of a plurality of strap assemblies to energize a set of coils of the individual ones of the plurality of strap assemblies wrapped around the elongate tube of the first and second formation sections. 
Postupak prema zahtjevu 1, 4 do 5 i 7 do 8, naznačen time, da faza formiranja i translatiranja FRC-konfiguracija uključuje uvođenje energije u komplet zavojnica od pojedinačnih od mnoštva rasponskih sklopova (230) koji su omotani oko izdužene cijevi od prvog i drugog tvorbenog dijela, gdje tvorbeni sustavi obuhvaćaju mnoštvo pogonskih i upravljačkih jedinica (220) spojenih na pojedinačne od mnoštva rasponskih sklopova.
Also described herein is a compound having a structure shown in Formula II, or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof: wherein: Ar is selected from the group consisting of phenyl and thiophen-yl; is selected from the group consisting of unsubstituted imidazolyl and substituted imidazolyl; 
Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen,a time, da: Ar je odabran iz skupine koju čine: fenil, supstituirani fenil, tiofen-il, supstituirani tiofen-il, piridinil, supstituirani piridinil, tiazolil, supstituirani tiazolil, pirimidinil, supstituirani pirimidinil, furanil, supstituirani furanil, biciklički aril, supstituirani biciklički aril, biciklički heteroaril i supstituirani biciklički heteroaril; R, je odabran iz skupine koju čine vodik i Cy-Cgalkil;
The composition according to claim 1 comprising about 2mg of buprenorphine. 
Pripravak sukladno patentnom zahtjevu 1 sadrži 2 mg buprenorfina.
Use of iota carrageenan in an antiviral effective amount in the manufacture of a medicament for the prophylactic or therapeutic topical treatment of viral eye infections caused by adenovirus of subtype D or influenza A virus of subtype H7, with the proviso that the composition in its ready-for-use formulation contains no more than 0.5% w/v of a metal halide salt. 
Jota- karagenan u antivirusno učinkovitoj količini za upotrebu u profilaktičkom ili terapeutskom topikalnom liječenju virusnih infekcija oka uzrokovanih adenovirusom podtipa D ili virusom A influence podtipa H7, uz ograničenje da pripravak u svojoj formulaciji spremnoj za primjenu sadrži ne više od 0.5 % w/v soli metalnog halogenida.
The device of claim 1, wherein the device further includes a clip affixed to the device, wherein the clip is configured to clip the device onto an object. The device of claim 2, wherein the clip is located on the removable cap. 
Uređaj prema zahtjevu 1, naznačen time, da uređaj dodatno obuhvaća kvačicu (110) pričvršćenu na uređaj, pri čemu je kvačica učinkovita za zakvačenje uređaja na neki objekt, 1 pritom je kvačica poželjno smještena na premjestivoj kapici (112).
An immunogenic composition according to any one of paragraphs 44 to 46 wherein the first proximal end and the second proximal end do not disrupt short repeat-long repeat-short repeat (SR-LR-SR) portions. 
Imunogeni pripravak u skladu s patentnim zahtjevom 10 ili patentnim zahtjevom 11, naznačen time što prvi proksimalni kraj i drugi proksimalni kraj ne prekidaju dijelove tipa kratko ponavljanje-dugo ponavljanje-kratko ponavljanje (SR-LR-SR).
A dose counter according to claim 2, wherein the gear wheel arranged for engagement by the second ratchet drive pawl is the second gear wheel coupled to the display, the second gear wheel having a circular arrangement of gear teeth. 
Brojač doza u skladu s patentnim zahtjevom 1, pri čemu je kotač sa zupčanikom koji je postavljen za pokretanje drugog pogona zapornog zaklopca (132) drugi kotač sa zupčanikom (130) povezan sa zaslonom, drugi kotač sa zupčanikom (130) ima kružno postavljene zupce zupčanika.
The isolated antibody or fragment of claim 1 or claim 2, comprising the heavy chain of SEQ ID NO: 220 and the light chain of SEQ ID NO: 156. 
Izolirano antitijelo ili fragment prema zahtjevu 1 ili zahtjevu 2, koji sadrži teški lanac SEK ID Br: 220 1 laki lanac SEK ID Br: 156.
A pharmaceutical composition for use in the treatment of ocular lubrication deficiency or symptoms associated therewith comprising PRG4 or a lubricating fragment thereof in combination with a therapeutically effective concentration of a PRG4-inducing compound selected from the group consisting of an androgen, a selective androgen receptor modulator, and an androgen analogue, wherein said androgen analogue is selected from the group consisting of 17a-methyl-17B-hydroxy-2-oxa-5a-androstan-3-one, 4,5a-dihydrotestosterone, and 19-nortestosterone, wherein said treatment comprises topical administration of said composition to an ocular surface. 
Farmaceutska kompozicija za primjenu u liječenju nedostatka okularne lubrikacije ili simptoma udruženih sa njim koja sadrži PRG4 ili njegov fragment za lubrikaciju u kombinaciji sa terapijski efikasnom koncentracijom PRG4-inducirajućeg spoja odabranog iz grupe koja se sastoji od androgena, selektivnog modulatora receptora androgena, i analoga androgena, pri čemu navedeni analog androgena je odabran iz grupe koja se sastoji od 17a-metil-17B-hidroksi-2-oksa-5a-androstan-3-ona, 4,5a-dihidrotestosterona, i 19-nortestosterona, pri čemu navedeno liječenje obuhvaća topikalnu administraciju navedenog spoja na okularnu površinu.
The pallet container of claim 10, wherein the internal layer and the external heat-resistant woven-fabric textile layer of the fire-protection insulation mat are configured for a unilateral long-term temperature stress of 1200° C. 
Paletni spremnik prema jednom od prethodnih patentnih zahtjeva 8-10 ili 12, naznačen time što je unutarnji netkani sloj (30) i vanjski sloj od tkanog tekstila (28) protupožarne izolacijske prostirke (20) zamišljen za jednostrano dugotrajno temperaturno naprezanje od 1200°C.
determining identification data of a subscriber who is associated with the mobile station on the basis of the detected identity reply signal; and 
određivanje (225) identifikacijskih podataka pretplatnika (145) koji je povezan sa navedenom mobilnom stanicom (140) na osnovu navedenog detektiranog signala odgovora identiteta; i
Inhibition of LDL oxidation 
Inhibicija LDL oksidacije
A compound according to claim 22 wherein the bacterial infection is an infection with a gram-positive bacterium. 
Spoj prema patentnom zahijevu 22, naznačen time da je bakterijska infekcija, infekcija sa gram-pozitivnom bakterijom. .
The fusion protein or the pharmaceutical composition for use of claim 31, wherein said autoimmune disease is selected from the group of type 1 diabetes, systemic lupus erythematosus, inflammatory bowel disease, Crohn's disease, ulcerative colitis and multiple sclerosis. 
Fuzijski protein ili farmaceutski pripravak za primjenu prema patentnom zahtjevu 31, naznačen time, da je spomenuta autoimuna bolest odabrana iz skupine bolesti dijabetesa tipa 1, sistemskog eritemskog lupusa, upalne bolesti crijeva, Crohnove bolesti, ulceroznog kolitisa i multiple skleroze.
reacting a compound of formula with a compound of formula in the presence of an activating agent to a compound of formula wherein the substituents are as defined in claim 1, or 
H sa spojem formule u prisutnosti agensa za aktivaciju do spoja formule naznačen time, da su supstituenti kao što je definirano u zahtjevu 1, ili b) reakciju spoja formule sa spojem formule 5